

Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer

T Yoshikawa¹, K Suzuki¹, O Kobayashi¹, M Sairenji¹, H Motohashi¹, A Tsuburaya¹, Y Nakamura², A Shimizu², S Yanoma³ and Y Noguchi⁴

¹The Third Department of Surgery, ²The First Department of Pathology and ³The Second Department of Biochemistry, Kanagawa Cancer Center, and ⁴The First Department of Surgery, Yokohama City University, School of Medicine, 1-1-2 Nakao, Asahi-Ku, Yokohama 241-0815, Japan

Summary Previous studies demonstrated that the immunohistochemical expression of thymidine phosphorylase (dThdPase) was related with distant metastasis and disease progression. In this study we investigated the production of dThdPase/platelet-derived endothelial cell growth factor in gastric cancer quantitatively. In a total of 75 tumour tissues and 60 normal gastric mucosa specimens, dThdPase protein concentrations were determined by ELISA. The amount of dThdPase was significantly higher in the tumour tissue than in the normal tissue. Intratumoural dThdPase concentrations were significantly higher in Borrmann types I and II macroscopically, in poorly differentiated and solid type histologically, in the medullary type of the tumour stroma, and in the tumour-invading serosa. In the medullary type of the amount of tumour stroma, protein levels of dThdPase were positively correlated with the vertical diameter of the tumour ($r = 0.580$, $P = 0.019$). By immunohistochemical study, dThdPase expression on tumour cells was observed in all seven specimens with high dThdPase protein levels, but not in all 14 cases with low dThdPase protein levels ($P < 0.05$). In summary, these data indicated that dThdPase is up-regulated in advanced solid types of gastric cancer, suggesting that dThdPase production in carcinoma cells might be induced by the microenvironment.

Keywords: thymidine phosphorylase; platelet-derived endothelial cell growth factor; gastric carcinoma

Thymidine phosphorylase (dThdPase) is an enzyme that is involved in pyrimidine nucleoside metabolism. It catalyses the reversible phosphorolysis of thymidine, deoxyuridine and their analogues to their respective bases and 2-deoxyribose-1-phosphate (Cook et al, 1979; Eda et al, 1993). Using dThdPase, 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU which is an anti-tumour drug used to treat a variety of neoplastic diseases such as gastric carcinoma (Ishitsuka et al, 1980; Miwa et al, 1987). As the expression of dThdPase is higher in tumours than in normal tissue (Kono et al, 1983; Nio et al, 1992), 5'-DFUR is used for several kinds of human tumours. However, to ensure suitable administration of 5'-DFUR, it is important to select the patients whose tumour tissue shows a much higher content of dThdPase.

Recently, it was reported that dThdPase is identical to platelet-derived endothelial cell growth factor (PD-ECGF) (Ishikawa et al, 1989; Furukawa et al, 1992). PD-ECGF stimulates chemotaxis of endothelial cells in vitro and has an angiogenic activity in vivo (Ishikawa et al, 1989; Miyazono et al, 1987). Experimental evidence has shown that angiogenesis plays a significant role in tumour growth and metastasis (Folkman, 1990; Folkman and Klagsbrun, 1987).

Thus far, the expression of dThdPase has been examined in a variety of types of neoplasm by immunohistochemistry, and its relations with prognosis, distant metastasis and disease progression

have been discussed (Maeda et al, 1996; Takebayashi et al., 1996a). However, neither the characteristics of tumours with much higher protein levels of dThdPase nor the regulatory mechanisms of dThdPase production in gastric cancer has been clarified.

In this study, in order to quantitatively assess the clinicopathological factors related to dThdPase and to elucidate the mechanisms of dThdPase induction, the intratumoural protein levels of dThdPase were determined by enzyme-linked immunosorbent assay (ELISA) in 75 gastric carcinoma tissues. For localization of dThdPase in cancer tissue, immunohistochemical studies were also performed.

MATERIALS AND METHODS

Patients

Tissue samples were obtained from 75 gastric cancer patients who underwent surgical resection at Kanagawa Cancer Center between August 1996 and February 1998. All patients were primary, except one patient with recurrent nodules of peritoneal dissemination. Classification of the resected gastric cancer tissues and pathological diagnosis were carried out according to the General Rules for the Gastric Cancer Study in Surgery and Pathology in Japan (Japanese Research Society for Gastric Cancer, 1995). Macroscopic types, based on Borrmann's classification, were as follows:

- type 0 – early gastric cancer
- types 1, 2, 3 and 4 – Borrmann types I, II, III and IV advanced gastric cancer
- type 5 – unclassified advanced gastric cancer (Japanese Research Society for Gastric Cancer, 1995).

Received 21 April 1998

Revised 15 June 1998

Accepted 13 July 1998

Correspondence to: T Yoshikawa

Preparations of tissue samples

Primary tumour tissues in 74 primary gastric cancer patients and a disseminated nodule in one recurrent patient were obtained during surgery. Normal gastric mucosa specimens were also resected in 60 primary tumour patients. Tissue samples were immediately frozen after the removal and stored at -80°C until processing. The frozen tissue samples were homogenized with phosphate-buffered saline (PBS) and centrifuged at 8000 g for 20 min. The supernatants were then used for the detection of the amount of dThdPase. The protein content was determined by DC protein assay (Bio-Rad, Hercules, CA, USA).

dThdPase assay

The amount of dThdPase protein was quantitated with ELISA as described (Nishida et al, 1996). Ninety-six-well microtiter plates were coated with $10\text{ }\mu\text{g/ml}$ of anti-human dThdPase monoclonal antibody 104B (Nippon Roche Research Center, Kanagawa, Japan) in PBS solution and then incubated with blocking solution containing skim milk. This antibody was prepared by using as an antigen human dThdPase purified from human colon cancer HCT116. The characterization of the antibody has been reported previously (Nishida et al, 1996). For the assay, $50\text{ }\mu\text{l}$ of properly diluted samples and serially diluted dThdPase (standards) were added to the wells and incubated for 2 h at 37°C , then washed with 0.05% Tween 20 in PBS and incubated with dThdPase monoclonal antibody 232-1. After washing the wells four times, $50\text{ }\mu\text{l}$ of anti-mouse IgG antiserum conjugated with peroxidase was added to the

wells and incubated for 1 h at room temperature. Wells were washed four times, and then the enzyme reaction was carried out at 37°C for 1 h with a substrate solution containing 3,3',5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide (TMB microwell peroxidase substrate system, KPL). The reaction was stopped by adding phosphoric acid and the absorbance at 450 nm was measured with a microplate reader. dThdPase contents were adjusted by the whole protein concentrations and expressed as unit/mg protein (U/mg protein).

Immunohistochemistry

For localization of dThdPase in gastric cancer tissue, immunohistochemical studies were performed on deparaffinized sections by the peroxidase-labelled streptavidin-biotin method using anti-dThdPase monoclonal antibody 654-1 (Nishida et al, 1996), provided by Nippon Roche Research Center, in seven tumour specimens with extremely high protein levels of dThdPase ($\leq 200\text{ U/mg}$ protein) and 14 tumour tissues with low protein levels of dThdPase ($< 70\text{ U/mg}$ protein). The clinicopathological characteristics of these cases are shown in Table 1.

Briefly, the sections were treated with skim milk in PBS at room temperature and incubated with the anti-dThdPase mouse monoclonal antibody ($1\text{ }\mu\text{g/ml}$) overnight at 4°C . After washing with PBS, the sections were further incubated with biotinylated anti-mouse IgG for 30 min at room temperature. Thereafter, the sections were treated with 1 mg/ml periodic acid in PBS for 10 min to block endogenous peroxidase activity. After being washed again with PBS, the sections were incubated with

Table 1 Clinicopathological characteristics in 21 cases selected for immunohistochemistry

Case	Macroscopic type	Vertical diameter (cm)	Histological type	Amount of tumour stroma	Depth of invasion	Venous invasion	dThdPase contents (U/mg protein)
<i>High levels of dThdPase protein ($\geq 200\text{ U/mg}$ protein)</i>							
1	1	2.2	Poorly differentiated and solid	Medullary	SE	Positive	210.0
2	3	2.5	Moderately differentiated tubular	Medullary	SE	Negative	217.4
3	3	1.4	Mucinous	Intermediate	SE	Negative	262.5
4	1	1.0	Moderately differentiated tubular	Intermediate	SE	Positive	411.9
5	2	1.4	Moderately differentiated tubular	Medullary	SI	Negative	210.3
6	2	1.0	Poorly differentiated and solid	Medullary	SE	Negative	310.8
7 ^a	2	2.0	Poorly differentiated and solid	Medullary	SE	Positive	459.2
<i>Low levels of dThdPase protein ($< 70\text{ U/mg}$ protein)</i>							
8	4	2.3	Poorly differentiated and non-solid	Scirrhus	SE	Negative	37.2
9	4	1.2	Poorly differentiated and non-solid	Scirrhus	SE	Positive	65.9
10 ^b	4	2.0	Poorly differentiated and non-solid	Scirrhus	SE	Negative	42.4
11	4	1.6	Poorly differentiated and non-solid	Scirrhus	SE	Negative	69.9
12	4	2.3	Mucinous	Scirrhus	SE	Positive	58.3
13	4	1.0	Poorly differentiated and non-solid	Scirrhus	SE	Negative	33.1
14	4	2.1	Poorly differentiated and non-solid	Scirrhus	SE	Positive	56.9
15	3	1.8	Poorly differentiated and solid	Intermediate	SE	Negative	53.0
16	2	0.8	Poorly differentiated and solid	Intermediate	SE	Positive	38.6
17	3	1.4	Mucinous	Intermediate	SE	Positive	67.5
18	3	1.2	Moderately differentiated tubular	Intermediate	SE	Positive	57.4
19	0	≤ 0.5	Moderately differentiated tubular	Medullary	M	Negative	48.7
20	0	≤ 0.5	Well differentiated tubular	Medullary	M	Negative	68.6
21	0	≤ 0.5	Moderately differentiated	Medullary	SM	Negative	62.3

^aImmunohistochemical findings in case 7, shown in Figure 4. ^bImmunohistochemical findings in case 10, shown in Figure 5. M, mucosal neoplastic involvement; SM, submucosal neoplastic involvement; SE, serosal involvement; SI, serosal involvement with directly infiltrating other organs beyond serosa. Macroscopic types are based on Borrmann's classification as follows: type 0, early gastric cancer; types 1, 2, 3 and 4, Borrmann's types I, II, III and IV advanced gastric cancer; type 5, unclassified advanced gastric cancer.




Figure 1 Distribution of tumour-normal (T/N) ratio of thymidine phosphorylase protein concentrations determined by ELISA

avidin-biotin complex (Vectastain ABC kit: Vector, Burlingame, CA, USA) for 30 min at room temperature and developed with 1 mg/ml diaminobenzidine tetrahydrochloride in PBS containing 0.03% hydrogen peroxide. The sections were also counterstained with methyl green and mounted.

We decided that the tumour cells should be regarded as dThdPase-positive when more than 50% of the tumour cells were stained. Infiltrating cells invading tumour tissue were also regarded as dThdPase-positive when more than 50% of the infiltrating cells were stained.

Statistical analysis

Comparisons between the two groups were performed by paired and unpaired Student's *t*-test and χ^2 method. For more than three groups, one-way analysis of variance (ANOVA) and Duncan's multiple range test were used. Correlations were evaluated by Spearman's test. $P < 0.05$ was considered to indicate statistical significance. Data were expressed as mean \pm SD.

RESULTS

The amount of dThdPase was significantly higher in the tumour tissue than in the normal tissue by paired Student's *t*-test (89.3 ± 86.6 U/mg protein, 36.8 ± 24.3 U/mg protein, respectively). The tumour-normal (T/N) ratios of dThdPase contents were more than 1.0 in 52 cases (86.7%), more than 2.0 in 29 cases (48.3%) and more than 3.0 in 16 cases (26.7%) of 60 cases examined (Figure 1).

Intratumoural dThdPase concentrations are shown in Table 2. dThdPase levels were significantly associated with macroscopic types, microscopic types and the amount of tumour stroma. In the macroscopic type, amounts of dThdPase were significantly higher in type 1 than in types 0, 3, 4 and 5, while those in type 2 were greater than in types 0, 4 and 5. In the microscopic type, poorly differentiated and solid type had significantly higher concentrations of dThdPase than well or moderately differentiated tubular type, poorly differentiated and non-solid type, and signet ring cell type. In the amount of tumour stroma, dThdPase levels were significantly higher in the medullary type than in other types (Figure 2). Although there was no significant difference among the depth of invasion by ANOVA, dThdPase protein levels in

Table 2 Intratumoural concentrations of dThdPase

	dThdPase (U/mg protein)	Statistics
Sex		NS
Male ($n = 51$)	99.6 ± 91.0	
Female ($n = 24$)	73.5 ± 47.9	
Macroscopic type ^a		$P < 0.05$
0 (Early gastric cancer, $n = 16$)	63.3 ± 31.2	
1 ($n = 5$)	181.9 ± 141.7	
2 ($n = 8$)	164.0 ± 154.0	
3 ($n = 14$)	103.0 ± 68.0	
4 ($n = 16$)	60.2 ± 31.1	
5 (Unclassified, $n = 15$)	69.3 ± 33.8	
Histological type		$P < 0.05$
Papillary ($n = 1$)	56.4	
Well differentiated tubular ($n = 8$)	58.8 ± 24.7	
Moderately differentiated tubular ($n = 18$)	106.6 ± 94.8	
Poorly differentiated and solid ($n = 10$)	172.3 ± 129.6	
Poorly differentiated and non-solid ($n = 24$)	60.8 ± 32.3	
Signet ring cell ($n = 6$)	63.2 ± 22.3	
Mucinous ($n = 7$)	102.9 ± 76.2	
Adenosquamous ($n = 1$)	117.7	
Lymph node metastasis		NS
Negative ($n = 25$)	70.8 ± 40.7	
Positive ($n = 49$)	100.2 ± 93.3	
Peritoneal dissemination		NS
Negative ($n = 58$)	97.1 ± 85.8	
Positive ($n = 17$)	71.2 ± 55.2	
Depth of invasion		NS
Mucosa ($n = 7$)	45.8 ± 21.6	
Submucosa ($n = 9$)	78.1 ± 30.6	
Muscularis propria ($n = 11$)	75.0 ± 40.2	
Subserosa ($n = 4$)	58.3 ± 20.2	
Serosa exposed ($n = 38$)	106.0 ± 102.8	
Serosa infiltrating ($n = 5$)	114.0 ± 69.9	
Lymphatic invasion		NS
Negative ($n = 25$)	91.9 ± 98.3	
Positive ($n = 48$)	89.3 ± 71.4	
Venous invasion		NS
Negative ($n = 48$)	81.9 ± 63.4	
Positive ($n = 24$)	108.3 ± 108.5	
Amount of stroma		$P < 0.05$
Medullary ($n = 17$)	145.4 ± 111.6	
Intermediate ($n = 23$)	96.0 ± 86.3	
Scirrhus ($n = 28$)	59.6 ± 27.1	
Stage		NS
Ia ($n = 15$)	60.7 ± 30.1	
Ib ($n = 7$)	85.8 ± 44.8	
II ($n = 7$)	73.5 ± 42.7	
IIIa ($n = 15$)	117.2 ± 106.5	
IIIb ($n = 11$)	135.2 ± 128.2	
IVa ($n = 4$)	54.4 ± 31.8	
IVb ($n = 15$)	79.4 ± 62.7	
Recurrence ($n = 1$)	165.3	

^aSee footnote to Table 1 for classification.

cases with serosal invasion ($n = 31$) were significantly higher than in cases without serosal invasion ($n = 43$) (106.9 ± 98.9 and 67.2 ± 33.1 , respectively, $P < 0.05$). There were no significant correlations between dThdPase and age, lymph node metastasis, peritoneal dissemination, lymphatic invasion, venous invasion and stages.

In the medullary type of the amount of tumour stroma, protein levels of dThdPase were positively correlated with the vertical diameter of the tumour (Table 3, Figure 3). The amounts of dThdPase were not significantly correlated with depth of invasion and the horizontal diameter of the tumour (Table 3).




Figure 2 dThdPase protein levels and the amount of stroma in cancer tissue




Figure 3 dThdPase protein levels and the vertical diameter in the medullary type of the amount of stroma

Table 3 Correlations between depth of invasion and maximal diameters in horizontal and vertical sections

	<i>r</i>	<i>P</i> -value
All cases (<i>n</i> = 74)		
Depth of invasion	0.101	0.404
Horizontal diameter	-0.04	0.973
Vertical diameter	0.146	0.226
Medullary type (<i>n</i> = 17)		
Depth of invasion	0.468	0.058
Horizontal diameter	0.310	0.227
Vertical diameter	0.580	0.019

The normal gastric mucosal cells were not stained with anti-dThdPase antibody. Unequivocal staining of cytoplasm and nuclear compartment were observed in most of the carcinoma cells in all seven specimens with high dThdPase protein levels (Table 4, Figure 4), while in all cases with low dThdPase levels, most of the

tumour cells were not stained (Table 4, Figure 5); there was a significant difference in the staining of carcinoma cells between these two groups by χ^2 test. dThdPase expression was often observed in the tumour cells invading vessels (Figure 6). On the other hand, the expression on macrophage-like cells on the stromal cells was observed in all 14 cases with low dThdPase levels and in four of seven cases with high levels (Table 4, Figures 4 and 5).

DISCUSSION

dThdPase has been reported to be increased in a variety of types of tumours (Kono et al, 1983; Nio et al, 1992). Carcinomas in the stomach contained higher amounts of dThdPase than non-neoplastic gastric mucosa (Yoshimura et al, 1990). As 5'-DFUR is metabolized to 5-FU by dThdPase (Miwa et al, 1987; Ishikawa et al, 1989), 5'-DFUR has been expected to be more specific and effective in tumour tissue than 5-FU. In this study, we demonstrated that dThdPase levels were increased in tumour tissue compared with those in normal mucosa in 86.7% of primary

Table 4 Site of production and the concentrations of dThdPase

	Tumour cells	Stromal cells
High contents (≥ 200 U/mg protein)	7/7	4/7
Medullary ($n = 5$)	5/5	2/5
Intermediate ($n = 2$)	2/2	2/2
Low contents (< 70 U/mg protein)	0/14	14/14
Medullary ($n = 3$) ^a	0/3	3/3
Intermediate ($n = 4$)	0/4	4/4
Scirrhus ($n = 7$)	0/7	7/7

^aAll cases were early gastric cancer.




Figure 4 Immunohistochemical staining for dThdPase (original magnification $\times 50$). There is a strong staining of cytoplasm and nuclear compartment of the tumour cells

gastric cancer patients; moreover, 48.3% of patients had more than two times the level of dThdPase in tumour tissue than appears in normal tissue. Higher T/N ratios of dThdPase activity are preferable in patients who are treated with 5'-DFUR, because of the probable high cytotoxicity against tumour tissue and the low toxicity against normal tissue. Determination of tissue levels of dThdPase would be useful for selecting the most appropriate patients for 5'-DFUR treatment.

To evaluate the characteristics of gastric carcinoma with high protein levels of dThdPase, clinicopathological findings were analysed. Our data demonstrated that dThdPase protein levels were increased in Borrmann types I and II macroscopically, in poorly differentiated and solid type histologically, in the medullary type of the tumour stroma, and in the tumour-invading serosa. In the medullary type of the amount of tumour stroma, dThdPase was positively correlated with the vertical diameter of the tumour. These data indicated that dThdPase is increased in advanced solid tumours in gastric cancer. Vascularization of advanced solid tumours is known to be poor and disordered, leading to insufficient perfusion and diffusion of nutrients to areas of the tumour (Griffiths and Stratford, 1997). This is thought to be a major reason for the existence of hypoxia, glucose depletion and low pH within solid tumours (Griffiths and Stratford, 1997). It was indicated that the expression of dThdPase was induced by hypoxia and low pH in human breast tumour cells (Griffiths et al, 1997). These mechanisms might be involved in higher amounts of dThdPase observed in advanced solid tumours in gastric cancer.




Figure 5 Immunohistochemical staining for dThdPase (original magnification $\times 100$). There is a strong staining in the stromal cells, but not in the tumour cells




Figure 6 Immunohistochemical staining for dThdPase in cancer cells invading vessels (original magnification $\times 40$). There is a strong staining of tumour cells inside the vessels

Previously, only two investigators evaluated the expression of dThdPase in gastric cancer by immunohistochemistry (Maeda et al, 1996; Takebayashi et al, 1996a). It was demonstrated that dThdPase expression was detected in 42% of gastric cancer and observed in gastric carcinoma cells but not in normal mucosa (Takebayashi et al, 1996a). It was also indicated that dThdPase expression was detected in 60.8% of gastric cancer and mainly observed in tumour cells but also sometimes in endothelial cells, lymphocytes or macrophages invaded into tumour stroma (Maeda et al, 1996). On the other hand, in colon and breast cancer, the production of dThdPase by infiltrating cells has been investigated and found to contribute to overall tumour levels (Takebayashi et al, 1996b). As shown in this study, dThdPase expression was observed in not only tumour cells but also stromal cells, suggesting that production in both of these cells would contribute to the overall dThdPase protein content in gastric cancer tissue. Moreover, the expression of dThdPase in tumour cells was mostly observed in the advanced solid type with high dThdPase protein content. These data support our hypothesis that dThdPase production in carcinoma cells might be induced by the microenvironment.

dThdPase in gastric cancer tissue was reported to be related to progression, metastasis and prognosis (Takebayashi et al, 1996a). It has also been indicated that dThdPase is associated with venous invasion, intratumoural microvessel count and hepatic metastasis, although that is not an independent prognostic factor in gastric cancer (Maeda et al, 1996). Our data did not indicate the relation of dThdPase levels with venous invasion and metastasis; however, dThdPase expression was often observed in the tumour cells invading vessels. It is likely that the evaluation by tumour cell staining observed by immunohistochemistry is different from the overall protein levels. dThdPase was not reported to be correlated with microvessel count in breast cancer (Fox et al, 1996). Fox et al (1996) suggested that dThdPase possibly involves in the early phase of angiogenesis as dThdPase is not mitogenic but chemotactic. In gastric cancer, hepatic metastasis was reported to be frequent in types 1 and 2 macroscopically, tubular type and poorly differentiated and solid type histologically, and medullary type of tumour stroma (Kito et al, 1981). As indicated in this study, dThdPase protein levels were increased in these types. Further investigation will be needed to clarify the role of dThdPase on hepatic metastasis in gastric cancer.

REFERENCES

- Cook AF, Holman MJ, Kramer MJ and Trown PW (1979) Fluorinated pyrimidine nucleoside. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. *J Med Chem* **22**: 1330-1335
- Eda H, Fujimoto K, Watanabe S, Ura M, Ura M, Hino A, Tanaka Y, Wada K and Ishitsuka H (1993) Cytokines induce thymidine phosphorylase expression in tumour cells and make them more susceptible to 5'-deoxy-5-fluorouridine. *Cancer Chemother Pharmacol* **32**: 333-338
- Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* **82**: 4-6
- Folkman J and Klagsbrun M (1987) Angiogenic factors. *Science* **235**: 442-447
- Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC and Harris AL (1996) The angiogenic factor, platelet derived endothelial cell growth factor thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. *Br J Cancer* **73**: 275-280
- Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M and Akiyama S (1992) Angiogenic factor. *Nature* **356**: 668
- Griffiths L and Stratford IJ (1997) Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. *Br J Cancer* **76**: 689-693
- Griffiths L, Dachs G, Bicknell R, Harris AL and Stratford IJ (1997) The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. *Cancer Res* **57**: 570-572
- Ishikawa F, Miyazono K, Hellmen U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku E, Risau W and Heldin C-H (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* **338**: 557-562
- Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama HD (1980) Role of uridine phosphorylase for anti-tumor activity of 5'-deoxy-5-fluorouridine. *Gann* **71**: 112-123
- Japanese Research Society for Gastric Cancer (1995) Japanese Classification of Gastric Carcinoma, First English Edition. Kanehara: Tokyo
- Kito T, Yamada E, Miyaishi S, Nakazato H, Kato H, Takagi M, Yasue T, Kato T, Morimoto S, Yamauchi S, Suchi T, Sato C and Suzuki R (1981) Prognosis and pathological type in advanced gastric cancer (in Japanese). *Geka* **43**: 1041-1046
- Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishituka H (1983) Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. *Chem Pharm Bull Tokyo* **31**: 175-178
- Maeda K, Chung YS, Ogawa Y, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y and Sowa M (1996) Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. *Br J Cancer* **73**: 884-888
- Miwa M, Nishimura J, Kamiyama T and Ishitsuka H (1987) Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients. *Jpn J Cancer Res* **14**: 2924-2929
- Miyazono K, Okabe T, Urabe A, Takaku F and Heldin CH (1987) Purification and properties of an endothelial cell growth factor from human platelets. *J Biol Chem* **262**: 4098-4103
- Nio Y, Kimura H, Tsubono M, Tseng CC, Kawabata K, Masai Y, Hayashi H, Meyer C, Fukumoto M and Tobe T (1992) Anti-tumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs. *Anticancer Res* **12**: 1141-1146
- Nishida M, Hino A, Kazushige M, Matsumoto T, Yoshikubo T and Ishitsuka H (1996) Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. *Biol Pharm Bull* **19**: 1407-1411
- Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T and Aikou T (1996a) Expression of thymidine phosphorylase in human gastric carcinoma. *Jpn J Cancer Res* **87**: 288-295
- Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita E, Aoki D, Okimura H, Yamada Y, Akiyama S and Aikou T (1996b) The activity and expression of thymidine phosphorylase in human solid tumors. *Eur J Cancer* **32**: 1227-1232
- Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K and Akiyama S (1990) Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. *Biochim Biophys Acta* **1034**: 107-113